Compare BioNano Genomics Inc (BNGO) vs CDW Corp. (CDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs CDW Corp. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while CDW Corp. trades at $135.37 (market cap $16.92B). The key difference: CDW Corp. is far larger — about 1238.7× BioNano Genomics Inc's market cap, and CDW Corp. pays a 1.86% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CDW | |
|---|---|---|
Market Cap | $13.66M | $16.92B |
Sector | Health | Technology |
52-Week High | $4.92 | $170.77 |
52-Week Low | $1.06 | $99.30 |
Enterprise Value | $16.26M | $22.52B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
CDW trades at $136.83, up 0.29% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.91, beating estimates, driven by 10% revenue growth from AI and infrastructure demand. However, margin compression and a CFO transition plan for 2027 present headwinds. The stock shows strong analyst support with a 70.59% buy rating and a $148.67 consensus price target.
Outlook remains positive due to solid fundamentals and AI-driven growth, but risks include margin pressure and leadership changes. The stock offers potential upside to the price target, though investors should monitor execution on profitability amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
